DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Collins DM, Conlon NT, Kannan S. et al.
Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer.
Cancers 2019;
11: 737
DOI: 10.3390/cancers11060737.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.